Idiopathic Adult Growth Hormone Deficiency
Open accessThe DOI matches its Crossref record; 83 of the 86 references it cites were found in a registry or an index.
Abstract
GH secretion is controlled by hypothalamic as well as intrapituitary and peripheral signals, all of which converge upon the somatotroph, resulting in integrated GH synthesis and secretion. Enabling an accurate diagnosis of idiopathic adult GH deficiency (IAGHD) is challenged by the pulsatility of GH secretion, provocative test result variability, and suboptimal GH assay standardization. The spectrum between attenuated GH secretion associated with the normal aging process and with obesity and truly well-defined IAGHD is not distinct and may mislead the diagnosis. Adult-onset GHD is mainly caused by an acquired pituitary deficiency, commonly including prior head/neck irradiation, or an expanding pituitary mass causing functional somatotroph compression. To what extent rare cryptic causes account for those patients seemingly classified as IAGHD is unclear. About 15% of patients with adult GHD and receiving GH replacement in open-label surveillance studies are reported as being due to an idiopathic cause. These patients may also reflect a pool of subjects with an as yet to be determined occult defect, or those with unclear or incomplete medical histories (including forgotten past sports head injury or motor vehicle accident). Therefore, submaximal diagnostic evaluation likely leads to an inadvertent diagnosis of IAGHD. In these latter cases, adherence to rigorous biochemical diagnostic criteria and etiology exclusion may result in reclassification of a subset of these patients to a distinct known acquired etiology, or as GH-replete. Accordingly, rigorously verified IAGHD likely comprises less than 10% of adult GHD patients, an already rare disorder. Regardless of etiology, patients with adult GHD, including those with IAGHD, exhibit a well-defined clinical phenotype including increased fat mass, loss of lean muscle mass, decreased bone mass, and enhanced cardiac morbidity. Definition of unique efficacy and dosing parameters for GH replacement and resultant therapeutic efficacy markers in true IAGHD requires prospective study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“while lean body mass improves by up to 7% during the first year of GH replacement (167,168).”
From Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [167]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Salomon, F., Cuneo, R. C., Hesp, R., & Sönksen, P. H. (1989) · New England Journal of Medicine · doi:10.1056/nejm198912283212605 · Cited by 1,326 · cited 2×
“The description of the adult GHD syndrome was rigorously defined in 1992 (1, 43, 44).”
BackgroundGiustina, A., & Veldhuis, J. D. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.6.0353 · Cited by 1,253 · cited 1×
“Declining GH pulse amplitude, rather than frequency, already starts occurring at the transition to young adulthood (13), and GH continues to decline thereafter with aging.”
BackgroundMelmed, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra062453 · Cited by 1,160 · cited 1×
“2006;355:2558–2573 (81), with permission.”
Self-citationMolitch, M. E., Clemmons, D. R., Malozowski, S., Merriam, G. R., & Vance, M. L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0179 · Cited by 1,047
Association between premature mortality and hypopituitarism
Tomlinson, J., Holden, N., Hills, R., Wheatley, K., Clayton, R., Bates, A., Sheppard, M., & Stewart, P. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04006-x · Cited by 1,006
Williams Textbook of Endocrinology
Reutrakul, S. (2009) · Medicine & Science in Sports & Exercise · doi:10.1249/01.mss.0000323673.44568.e8 · Cited by 711
Acromegaly pathogenesis and treatment
Melmed, S. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39375 · Cited by 687
Self-citationHo, K. K. Y., & _, _. (2007) · European Journal of Endocrinology · doi:10.1530/eje-07-0631 · Cited by 615
Schneider, H. J., Kreitschmann-Andermahr, I., Ghigo, E., Stalla, G. K., & Agha, A. (2007) · JAMA · doi:10.1001/jama.298.12.1429 · Cited by 549 · cited 1×
“For example, GHD has been reported by 1 group in patients with primary hyperparathyroidism (58) and also after subarachnoid hemorrhage (56).”
BackgroundThe effect of hypopituitarism on life expectancy.
Bates, A. S., Van't Hoff, W., Jones, P. J., & Clayton, R. N. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.3.8772595 · Cited by 475
Mechanisms for pituitary tumorigenesis: the plastic pituitary
Melmed, S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200320401 · Cited by 456 · cited 1×
“Because the somatotroph cell is most sensitive to early pituitary insults, including trauma, radiation, and gland compression, adult GHD usually precedes development of multiple pituitary hormone deficits, including more readily recognizable gonadal, thyroid, or adrenal failure (65) (Figure 3).”
BackgroundSelf-citationHypopituitarism Following External Radiotherapy for Pituitary Tumours in Adults
LITTLEY, M. D., SHALET, S. M., BEARDWELL, C. G., AHMED, S. R., APPLEGATE, G., & SUTTON, M. L. (1989) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a068308 · Cited by 444
Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency
Biller, B. M. K., Samuels, M. H., Zagar, A., Cook, D. M., Arafah, B. M., Bonert, V., Stavrou, S., Kleinberg, D. L., Chipman, J. J., & Hartman, M. L. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.5.8509 · Cited by 423 · cited 1×
“1 g/L, respectively, with a 96% sensitivity and 92% specificity as assessed by receiver operating characteristic analysis (32).”
MethodHypopituitarism Secondary to Head Trauma
Benvenga, S. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.4.1353 · Cited by 423
Attanasio, A. F., Lamberts, S. W. J., Matranga, A. M. C., Birkett, M. A., Bates, P. C., Valk, N. K., Hilsted, J., Bengtsson, B.-Å., & Strasburger, C. J. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.1.3643 · Cited by 380 · cited 3×
“In fact, published clinical efficacy studies for GH replacement do not uniformly address the distinctive “idiopathic” adult GHD patient (3, 51).”
BackgroundThe growth hormone deficiency syndrome in adults
Cuneo, R. C., Salomon, F., McGauley, G. A., & Sönksen, P. H. (1992) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1992.tb02347.x · Cited by 375 · cited 1×
“The description of the adult GHD syndrome was rigorously defined in 1992 (1, 43, 44).”
BackgroundThe growth hormone receptor: mechanism of activation and clinical implications
Brooks, A. J., & Waters, M. J. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.123 · Cited by 357 · cited 1×
“Peripheral GH signaling is mediated by the ubiquitous GH receptor, a class 1 dimeric cytokine receptor (15) acting predominantly but not exclusively through STAT-5.”
BackgroundClemmons, D. R. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.150631 · Cited by 353
Schneider, H. J., Aimaretti, G., Kreitschmann-Andermahr, I., Stalla, G.-K., & Ghigo, E. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60673-4 · Cited by 336
Which Patients Do Not Require a GH Stimulation Test for the Diagnosis of Adult GH Deficiency?
Hartman, M. L. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.2.477 · Cited by 319 · cited 2×
“Accordingly, the likelihood of adult GHD already being present in patients with known multiple pituitary hormone failure is high (42).”
BackgroundArafah, B. M. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.5.1789 · Cited by 270
Abs, R., Bengtsson, B., Hernberg‐Ståhl, E., Monson, J. P., Tauber, J., Wilton, P., & Wüster, C. (1999) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1999.00695.x · Cited by 267 · cited 9×
“The long-term safety profile for new cancers and diabetes in GHD adults appears favorable, but it is currently being further assessed in long-term surveillance studies (6, 77, 78).”
BackgroundInfluentialPrevalence of Neuroendocrine Dysfunction in Patients Recovering from Traumatic Brain Injury
Lieberman, S. A. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.6.2752 · Cited by 261
Pituitary somatostatin receptor signaling
Ben-Shlomo, A., & Melmed, S. (2010) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2009.12.003 · Cited by 213 · cited 1×
“Hypothalamic somatostatin is the primary signal attenuating GH release, mediated predominantly by somatotroph SSTR2 signaling to block GH secretion (11).”
BackgroundSelf-citationWang, J., Zhou, J., Cheng, C., Kopchick, J., & Bondy, C. (2004) · Journal of Endocrinology · doi:10.1677/joe.0.1800247 · Cited by 197 · cited 1×
“Several additional mediators, including those required for myoblast fusion (16) and chondrocyte growth (17) have also recently been”
BackgroundHoffman, A. R., Kuntze, J. E., Baptista, J., Baum, H. B. A., Baumann, G. P., Biller, B. M. K., Clark, R. V., Cook, D., Inzucchi, S. E., Kleinberg, D., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030346 · Cited by 185 · cited 4×
“In fact, published clinical efficacy studies for GH replacement do not uniformly address the distinctive “idiopathic” adult GHD patient (3, 51).”
BackgroundInfluentialGH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults
Popovic, V., Leal, A., Micic, D., Koppeschaar, H. P., Torres, E., Paramo, C., Obradovic, S., Dieguez, C., & Casanueva, F. F. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02755-0 · Cited by 185
Systematic Review: The Effects of Growth Hormone on Athletic Performance
Liu, H., Bravata, D. M., Olkin, I., Friedlander, A., Liu, V., Roberts, B., Bendavid, E., Saynina, O., Salpeter, S. R., Garber, A. M., et al. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-10-200805200-00215 · Cited by 183 · cited 1×
“Thus, GH abuse by athletes or inappropriate GH administration to pituitary-replete subjects entails a significant health risk (74).”
BackgroundHypopituitarism following radiation therapy of pituitary adenomas
Snyder, P. J., Fowble, B. F., Schatz, N. J., Savino, P. J., & Gennarelli, T. A. (1986) · The American Journal of Medicine · doi:10.1016/0002-9343(86)90299-8 · Cited by 167
Clasey, J. L. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.8.3845 · Cited by 167 · cited 1×
“In addition, age-related abdominal fat mass and hyperinsulinemia are associated with further age-related declines in GH secretion (39).”
BackgroundGiannoulis, M. G., Sonksen, P. H., Umpleby, M., Breen, L., Pentecost, C., Whyte, M., McMillan, C. V., Bradley, C., & Martin, F. C. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0957 · Cited by 164 · cited 1×
“and maximal O2 consumption (VO2 max) (69, 70) and enhance sprint capacity by 4% (71), as well as increase anaerobic capacity.”
BackgroundSotiropoulos, A., Ohanna, M., Kedzia, C., Menon, R. K., Kopchick, J. J., Kelly, P. A., & Pende, M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510033103 · Cited by 158 · cited 1×
“Several additional mediators, including those required for myoblast fusion (16) and chondrocyte growth (17) have also recently been”
BackgroundThe history of doping and growth hormone abuse in sport
Holt, R. I. G., Erotokritou‐Mulligan, I., & Sönksen, P. H. (2009) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2009.04.009 · Cited by 143 · cited 1×
“GH has also been extensively used by athletes in an attempt to enhance performance (68).”
BackgroundYamashita, S., & Melmed, S. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112832 · Cited by 139
Self-citationLocus Control Region Transcription Plays an Active Role in Long-Range Gene Activation
Ho, Y., Elefant, F., Liebhaber, S. A., & Cooke, N. E. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.05.041 · Cited by 128 · cited 1×
“About 10% of secreted GH lacks aa residues 32–46, accounting for a 20-kDa variant (9).”
BackgroundMeinhardt, U., Nelson, A. E., Hansen, J. L., Birzniece, V., Clifford, D., Leung, K.-C., Graham, K., & Ho, K. K. Y. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-9-201005040-00007 · Cited by 127
Rosilio, M., Blum, W. F., Edwards, D. J., Shavrikova, E. P., Valle, D., Lamberts, S. W. J., Erfurth, E. M., Webb, S. M., Ross, R. J., Chihara, K., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030134 · Cited by 122 · cited 1×
“mass, improving cardiovascular function and exercise capacity, and increasing bone density (3, 51, 66, 67) (Table 3).”
BackgroundLong-term experience with GH replacement therapy: efficacy and safety
Monson, J. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.148s009 · Cited by 120 · cited 1×
“The long-term safety profile for new cancers and diabetes in GHD adults appears favorable, but it is currently being further assessed in long-term surveillance studies (6, 77, 78).”
BackgroundMakimura, H., Stanley, T., Mun, D., You, S. M., & Grinspoon, S. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1333 · Cited by 118 · cited 1×
“Importantly, peak GH levels elicited by Arg-GHRH were shown to be blunted by 1 g/L for each 1-cm increase in waist circumference (36).”
BackgroundBonert, V. S., Elashoff, J. D., Barnett, P., & Melmed, S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032213 · Cited by 117
Self-citationFactors Regulating Growth Hormone Secretion in Humans
Goldenberg, N., & Barkan, A. L. (2007) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2006.11.003 · Cited by 115 · cited 2×
“The net result of these positive and negative inputs is an episodic release of GH characterized by unique secretory determined by gender (sexual dimorphic patterns), age (attenuation), and sleep (augmentation) patterns (14).”
BackgroundGenetic causes and treatment of isolated growth hormone deficiency—an update
Alatzoglou, K. S., & Dattani, M. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.147 · Cited by 109 · cited 1×
“ital or genetic childhood disorder (64).”
Brief communication: pituitary volume and function in competing and retired male boxers
Tanriverdi, F., Unluhizarci, K., Kocyigit, I., Tuna, I. S., Karaca, Z., Durak, A. C., Selcuklu, A., Casanueva, F. F., & Kelestimur, F. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-11-200806030-00005 · Cited by 100 · cited 1×
“Competitive contact sports participation, especially boxing and football, have been unmasked as important factors contributing to adult GHD (57).”
BackgroundYamamoto, M., Iguchi, G., Takeno, R., Okimura, Y., Sano, T., Takahashi, M., Nishizawa, H., Handayaningshi, A. E., Fukuoka, H., Tobita, M., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44073 · Cited by 97 · cited 1×
“More recently, specific circulating autoantibodies to PIT-1 were reported in 3 adults with combined GH, prolactin, and TSH deficiency (61).”
BackgroundHartman, M. L., Xu, R., Crowe, B. J., Robison, L. L., Erfurth, E. M., Kleinberg, D. L., Zimmermann, A. G., Woodmansee, W. W., Cutler, G. B., Chipman, J. J., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2684 · Cited by 88
Self-citationTen years of growth hormone (GH) replacement normalizes muscle strength in GH-deficient adults
Götherström, G., Elbornsson, M., Stibrant-Sunnerhagen, K., Bengtsson, B.-A., Johannsson, G., & Svensson, J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1538 · Cited by 85 · cited 1×
“mass, improving cardiovascular function and exercise capacity, and increasing bone density (3, 51, 66, 67) (Table 3).”
BackgroundYuen, K. C. J., Biller, B. M. K., Molitch, M. E., & Cook, D. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0299 · Cited by 84
Aimaretti, G., Baffoni, C., Bellone, S., Di Vito, L., Corneli, G., Arvat, E., Benso, L., Camanni, F., & Ghigo, E. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.10.6858 · Cited by 83
Growth hormone and physical performance
Birzniece, V., Nelson, A. E., & Ho, K. K. Y. (2011) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2011.02.005 · Cited by 78 · cited 2×
“Data are presented as a range of percentages of the subjects reporting side effects during GH and placebo administration (20).”
BackgroundThe safety profile of GH replacement therapy in adults
Chipman, J. J., Attanasio, A. F., Birkett, M. A., Bates, P. C., Webb, S., & Lamberts, S. W. J. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.1660984.x · Cited by 76 · cited 1×
“Dose-dependent side effects of GH replacement to truly GH-deficient adults are reported in up to 30% of patients and include arthralgia, myalgias, edema, paresthesia and carpal tunnel syndrome (3, 75), sleep apnea, insomnia, and dyspnea (76).”
BackgroundAttanasio, A. F., Jung, H., Mo, D., Chanson, P., Bouillon, R., Ho, K. K. Y., Lamberts, S. W. J., Clemmons, D. R., & for the HypoCCS International Advisory Board (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0448 · Cited by 74 · cited 1×
“The long-term safety profile for new cancers and diabetes in GHD adults appears favorable, but it is currently being further assessed in long-term surveillance studies (6, 77, 78).”
BackgroundLuque, R. M., Lin, Q., Córdoba-Chacón, J., Subbaiah, P. V., Buch, T., Waisman, A., Vankelecom, H., & Kineman, R. D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0015767 · Cited by 73 · cited 1×
“In fact, in a unique transgenic mouse model of selective somatotroph ablation, recapitulating the disorder of isolated GHD, insulin sensitivity was actually enhanced independently of diet (41).”
BackgroundGleeson, H. K., Gattamaneni, H. R., Smethurst, L., Brennan, B. M., & Shalet, S. M. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031224 · Cited by 72
Colao, A., Di Somma, C., Savastano, S., Rota, F., Savanelli, M. C., Aimaretti, G., & Lombardi, G. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1134 · Cited by 69
Pituitary Physiology and Diagnostic Evaluation
Melmed, S. K., Kleinberg, D. L., & Ho, K. K. Y. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00008-0 · Cited by 64
Self-citationDe Bellis, A., Pane, E., Bellastella, G., Sinisi, A. A., Colella, C., Giordano, R., Giavoli, C., Lania, A., Ambrosio, M. R., Di Somma, C., et al. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04056.x · Cited by 62
Webb, S. M., Strasburger, C. J., Mo, D., Hartman, M. L., Melmed, S., Jung, H., Blum, W. F., Attanasio, A. F., & on behalf of the HypoCCS International Advisory Board (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0713 · Cited by 59
Self-citationBellastella, G., Rotondi, M., Pane, E., Dello Iacovo, A., Pirali, B., Dalla Mora, L., Falorni, A., Sinisi, A. A., Bizzarro, A., Colao, A., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0551 · Cited by 59
Growth hormone-releasing hormone as an agonist of the ghrelin receptor GHS-R1a
Casanueva, F. F., Camiña, J. P., Carreira, M. C., Pazos, Y., Varga, J. L., & Schally, A. V. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811680106 · Cited by 58 · cited 1×
“GH synthesis and release are induced by hypothalamic GHRH, signaling through the G protein-coupled GHRH receptor to induce somatotroph cAMP, and also by ghrelin, predominantly derived from the gastrointestinal tract (10).”
BackgroundVeldhuis, J. D., Roelfsema, F., Keenan, D. M., & Pincus, S. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1669 · Cited by 53 · cited 1×
“Because the somatotroph axis is attenuated with age, especially in men, the use of random GH measurements may lead to an inadvertent diagnosis of IAGHD and subsequent inappropriate GH replacement in patients 50 years old (29, 37).”
BackgroundGraham, M. R., Baker, J. S., Evans, P., Kicman, A., Cowan, D., Hullin, D., Thomas, N., & Davies, B. (2008) · Hormone Research in Paediatrics · doi:10.1159/000117390 · Cited by 52 · cited 1×
“and maximal O2 consumption (VO2 max) (69, 70) and enhance sprint capacity by 4% (71), as well as increase anaerobic capacity.”
BackgroundEndocrine dysfunction in patients operated on for non-pituitary intracranial tumors
Schneider, H. J., Rovere, S., Corneli, G., Croce, C. G., Gasco, V, Rudà, R., Grottoli, S., Stalla, G. K., Soffietti, R., Ghigo, E., et al. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02272 · Cited by 51
Characterization of Growth Hormone of Different Molecular Weights in Rat, Dog and Human Pituitaries
Frohman, L. A., BUREK, L., & Stachura, M. E. (1972) · Endocrinology · doi:10.1210/endo-91-1-262 · Cited by 45 · cited 1×
“The normal adult pituitary gland contains up to 15 mg GH stored mainly in prominent secretory granules approximately 700 m in diameter (8).”
BackgroundSupraphysiological Doses of GH Induce Rapid Changes in Cardiac Morphology and Function
Cittadini, A., Berggren, A., Longobardi, S., Ehrnborg, C., Napoli, R., Rosén, T., Fazio, S., Caidahl, K., Bengtsson, B., & Saccà, L. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.4.8363 · Cited by 45 · cited 1×
“However, in GH-replete subjects, inappropriate GH administration may cause edema, sweating, fatigue, and in higher doses, diabetes and cardiac dysfunction (79, 80) (Figure 4).”
BackgroundStatement by the Growth Hormone Research Society on the GH/IGF-I Axis in Extending Health Span
Thorner, M. O. (2009) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glp091 · Cited by 45 · cited 1×
“Whether or not decreased GH levels associated with aging are beneficial to overall health and well-being remains controversial (40).”
BackgroundImpairment of GH secretion in adults with primary empty sella
Gasperi, M., Aimaretti, G., Cecconi, E., Colao, A., Somma, C. D., Cannavò, S., Baffoni, C., Cosottini, M., Curtò, L., Trimarchi, F., et al. (2002) · Journal of Endocrinological Investigation · doi:10.1007/bf03344013 · Cited by 44
Diagnosis of adult GH deficiency
Gasco, V., Corneli, G., Rovere, S., Croce, C., Beccuti, G., Mainolfi, A., Grottoli, S., Aimaretti, G., & Ghigo, E. (2008) · Pituitary · doi:10.1007/s11102-008-0110-x · Cited by 41 · cited 3×
“Although insulin-induced hypoglycemia (ITT) is the reference “gold standard” for diagnosis of GHD, GHRH arginine, GHRH GHreleasing peptide, GH-releasing peptide and glucagon are also commonly employed (2, 4, 29, 30).”
BackgroundMethodBrabant, G., Poll, E. M., Jönsson, P., Polydorou, D., & Kreitschmann-Andermahr, I. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0273 · Cited by 41 · cited 1×
“6% in The Netherlands to 65% in the United Kingdom; 57% of US patients were classified as IAGHD, whereas only 20% harbored a pituitary adenoma (45).”
BackgroundKlose, M., Jonsson, B., Abs, R., Popovic, V, Koltowska-Häggström, M., Saller, B., Feldt-Rasmussen, U., & Kourides, I. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0328 · Cited by 31 · cited 1×
“Furthermore, patients with increased central adiposity may have exhibited blunted GH responses and been inadvertently included in published observational studies (3, 5, 6, 51, 52).”
BackgroundCharacteristics of adults who wish to enter a trial of growth hormone replacement
Holmes, S. J., & Shalet, S. M. (1995) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1995.tb02688.x · Cited by 30
Murray, R. D., Bidlingmaier, M., Strasburger, C. J., & Shalet, S. M. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2055 · Cited by 28 · cited 3×
“Thus, the continuum of somatotroph-replete patients may also comprise a subset who are GH “insufficient” and may yet evolve to develop full-fledged adult GHD (53).”
BackgroundInfluentialGH Secretion Is Impaired in Patients with Primary Hyperparathyroidism
Gasperi, M., Cecconi, E., Grasso, L., Bartalena, L., Centoni, R., Aimaretti, G., Broglio, F., Miccoli, P., Marcocci, C., Ghigo, E., et al. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.5.8451 · Cited by 24 · cited 1×
“For example, GHD has been reported by 1 group in patients with primary hyperparathyroidism (58) and also after subarachnoid hemorrhage (56).”
BackgroundNew Developments in the Illegal Provision of Growth Hormone for “Anti-Aging” and Bodybuilding
Olshansky, S. J. (2008) · JAMA · doi:10.1001/jama.299.23.2792 · Cited by 24 · cited 2×
“In light of the current propensity for inappropriate adult GH prescriptions (19), the diagnosis of IAGHD should only be made in those patients with attenuated GH response to at least 2 stimulation agents.”
Backgroundvan Nieuwpoort, I. C., van Bunderen, C. C., Arwert, L. I., Franken, A. A. M., Koppeschaar, H. P. F., van der Lelij, A. J., Twisk, J. W. R., Boers, M., & Drent, M. L. (2011) · European Journal of Endocrinology · doi:10.1530/eje-10-0914 · Cited by 23 · cited 1×
“(46) and in 13% of adult GHD patients in Sweden (47).”
BackgroundChanson, P., Cailleux-Bounacer, A., Kuhn, J.-M., Weryha, G., Chabre, O., Borson-Chazot, F., Dubois, S., Vincent-Dejean, C., Brue, T., Fedou, C., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0295 · Cited by 22 · cited 1×
“Although insulin-induced hypoglycemia (ITT) is the reference “gold standard” for diagnosis of GHD, GHRH arginine, GHRH GHreleasing peptide, GH-releasing peptide and glucagon are also commonly employed (2, 4, 29, 30).”
MethodSupplemental growth hormone in healthy adults: the endocrinologist's responsibility
Melmed, S. K. (2006) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0138 · Cited by 17
Self-citationYoung, J., & Anwar, A. J. (2007) · British Journal of Sports Medicine · doi:10.1136/bjsm.2006.030585 · Cited by 17
Fleetwood, M. R., Ho, Y., Cooke, N. E., & Liebhaber, S. A. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.365825 · Cited by 16 · cited 1×
“dant pituitary-specific hGH-N transcription (7).”
Partial growth hormone deficiency in adults; should we be looking for it?
Shalet, S. M. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03809.x · Cited by 14 · cited 2×
“GH replacement therapy should only be offered to those patients rigorously diagnosed by evidence-based criteria as being GH-deficient and in whom a clear etiology for the disorder has been established (18, 23).”
BackgroundNyström, H. F., Saveanu, A., Barbosa, E. J. L., Barlier, A., Enjalbert, A., Glad, C. A. M., Palming, J., Johannsson, G., & Brue, T. C. (2010) · Pituitary · doi:10.1007/s11102-010-0278-8 · Cited by 13
Enhancement of the peripheral sensitivity to growth hormone in adults with GH deficiency
Aimaretti, G., Fanciulli, G., Bellone, S., Maccario, M., Arvat, E., Delitala, G., Camanni, F., & Ghigo, E. (2001) · European Journal of Endocrinology · doi:10.1530/eje.0.1450267 · Cited by 13 · cited 1×
“Interestingly, although IGF-I levels also decline with aging, liver IGF-I responses to administered GH appear appropriate, suggesting intact age-associated peripheral GH sensitivity (38).”
BackgroundAcromegaly Induced by Growth Hormone Replacement Therapy
Karges, B., Pfäffle, R. W., Boehm, B. O., & Karges, W. (2004) · Hormone Research in Paediatrics · doi:10.1159/000076007 · Cited by 12
Lipworth, W. L., Ho, K. K. Y., Kerridge, I., & Day, R. O. (2012) · The Medical Journal of Australia · doi:10.5694/mja11.11572 · Cited by 9 · cited 2×
“GH replacement therapy should only be offered to those patients rigorously diagnosed by evidence-based criteria as being GH-deficient and in whom a clear etiology for the disorder has been established (18, 23).”
Background
Cited by
Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
Fleseriu, M., Hashim, I. A., Karavitaki, N., Melmed, S., Murad, M. H., Salvatori, R., & Samuels, M. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2118 · Cited by 945
Self-citationInfluence of body weight on bone mass, architecture and turnover
Iwaniec, U. T., & Turner, R. T. (2016) · Journal of Endocrinology · doi:10.1530/joe-16-0089 · Cited by 199
“An age-related decrease in growth hormone secretion (Melmed 2013, Sattler 2013) contributes to muscle atrophy and bone loss in humans (Kuzma et al.”
Pathogenesis and Diagnosis of Growth Hormone Deficiency in Adults
Melmed, S. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1817346 · Cited by 173
Self-citationBasu, R., Qian, Y., & Kopchick, J. J. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0018 · Cited by 72
Heppner, K. M., & Tong, J. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0183 · Cited by 71
Metadata
- Authors
- Melmed, S.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Corresponding author
- Melmed, Shlomo
- ORCID
- Melmed, Shlomo
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2013-06-01
- Volume
- 98
- Issue
- 6
- Pages
- 2187-2197
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC3667267
- OpenAlex
- W2059203397
- Semantic Scholar
- 333dabc829dcdc57a0f6e139fad0429a3141970f
- Cited by
- 58
- References
- 86
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 5 · 2022: 3 · 2021: 2 · 2020: 4 · 2019: 5 · 2018: 4 · 2017: 5 · 2016: 9 · 2015: 4 · 2014: 9 · 2013: 2
- FWCI
- 1.18
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Cedars-Sinai Medical Center
- National Institutes of Health
- National Cancer Institute (R01CA075979, CA-75979)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- growth hormone secretion, somatotrophs, hypopituitarism, head and neck radiotherapy, growth hormone replacement therapy, obesity, bone mass, cardiac morbidity, diagnostic criteria
- MeSH terms
- Adult, Humans, Human Growth Hormone, Hormone Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.